Objective: Gestational diabetes (GDM) is characterized by maternal glucose intolerance that manifests during pregnancy. Because GDM resembles type 2 diabetes (T2DM), shared genetic predisposition is likely but has not been established. We tested the hypothesis that a genetic risk score (GRS) that included variants known to be associated with T2DM is associated with GDM.
| INTRODUCTION
Gestational diabetes (GDM) is characterized by maternal glucose intolerance that manifests during pregnancy. It occurs in approximately 9% of all pregnancies and is estimated to affect more than 200 000 pregnant women annually in the United States.
1 GDM has important clinical implications because it is associated with significant short-and long-term adverse health consequences for women and their children.
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Normal pregnancy is characterized by a progressive decrease in insulin sensitivity that begins in the second trimester and can reach levels observed in type 2 diabetes (T2DM) during the third trimester.
To compensate for this pregnancy-induced insulin resistance, pancreatic β-cells increase insulin release. 3 However, in some women the amount of insulin released cannot meet the increased requirements, resulting in GDM. 2, 3 The pathogenesis of GDM is similar to T2DM, which is also characterized by insulin resistance followed by a compensatory increase in insulin secretion that is unable to meet requirements. 4 GDM and T2DM share not only similar pathophysiology but also similar risk factors; GDM increases the likelihood of developing T2DM later in life, 5 and women with a family history of T2DM have higher risk of developing GDM. 6 Thus, it is likely that both conditions, to some degree, have a common genetic susceptibility.
Indeed, some genetic variants in selected T2DM risk loci have been associated with the risk of GDM with modest effects. [7] [8] [9] Thus, similar to T2DM, it is possible that variants in several loci, each with small individual effects, contribute to the risk of GDM in a cumulative fashion. Thus, measuring their joint contribution may result in a stronger genetic signal than that provided by single variants.
We therefore examined the hypothesis that a genetic risk score that included variants known to be associated with T2DM and glucose in the general population, as well as variants previously associated with GDM and glucose intolerance during pregnancy, is associated with risk of GDM. The risk score included variants in loci known to affect β-cell function (KNCQ1, KCNJ11, SLC30A8, etc.) or insulin sensitivity (eg FTO, IRS1, PPARG) and in loci associated with T2DM through mechanisms that are unclear (eg DUSP9 and HMG20A).
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To test this hypothesis, we conducted a case-control study examining the combined effect of these variants on the risk of GDM.
| METHODS

| Study design
The study was performed using the Vanderbilt University Medical 
| Definition of cases and controls
We first selected women in BioVU that met the following criteria: (i) aged ≥18 years old, (ii) Caucasian, (iii) one or more pregnancy-related ICD9 or CPT codes, (iv) no diabetes-related ICD9-(250.**) codes before a pregnancy code. The study population included pregnant women with a DNA sample who had delivered or received pregnancy care between 1994 and 2016 at VUMC. Then, to ascertain potential cases of GDM, we used bioinformatic algorithms to search for women who had a 100-g oral glucose tolerance test (100-g OGTT) diagnostic of GDM using Carpenter and Coustan criteria 12 or had two or more ICD9 codes for glucose intolerance during pregnancy (648.83) (Figure 1 ). We then reviewed the de-identified EMRs of these potential cases to identify confirmed cases of GDM, defined as a pregnant woman who: (i) had a 100-g OGTT diagnostic of GDM using
Carpenter and Coustan criteria, 12 (ii) had diagnosis of GDM made by a physician, or (iii) had received an intervention for GDM (nutritional or antidiabetic medication). In the United States, the National Institutes of Health decision-making panel recommends a two-step approach to rule out GDM. This includes a 1-h 50-g glucose challenge test (50-g GCT) followed by the 3-h 100-g OGTT for those who screen positive in the 50-g GCT.
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We excluded potential cases that did not have enough clinical information to support the diagnosis of GDM, and those with diabetes before pregnancy. We also excluded cases receiving an antidiabetic medication at the time of screening for GDM, and those with a drug exposure or disease that may have affected the 100-g OGTT (eg highdose glucocorticoids, cystic fibrosis and pancreatic insufficiency). For cases with more than one qualifying pregnancy with GDM, we used the first.
Screening for GDM is performed routinely between 24 and 28 weeks of pregnancy with a 50-g GCT. To identify potential controls, we selected pregnant women who had a normal 50-g GCT (<140 mg/ dL) ( Figure 1 ). We frequency-matched cases and controls by age (±5 years) and gestation type (singleton and multiple pregnancy). We excluded potential controls with inadequate clinical information and those with a previous history of GDM.
| Clinical covariates
Using bioinformatic approaches and manual chart review, we extracted clinically relevant covariates such as: parity, height, prepregnancy weight, predelivery weight, and gestational age at delivery. We calculated the date of conception by subtracting the gestational age at delivery from the delivery date. If the gestational age at delivery was not recorded, we used the gestational age at the earliest prenatal care visit to calculate the date of conception. We defined prepregnancy weight as the weight measured closest to the date of conception within the 2 years before and 12 weeks after the date of conception.
If the closest weight was measured between weeks 8 and 12 after conception, we subtracted 0.45 kg from this weight.
14 Weights that overlapped with a previous pregnancy were excluded. We considered predelivery weight to be a weight recorded in the 15 days before delivery. We calculated body mass index (BMI) by dividing weight (in kilograms) by the square of height (in metres).
| Genotyping
We genotyped 34 SNPs that included: 18 SNPs for loci that had been significantly associated (P<5×10 −8 ) with T2DM or fasting glucose in two or more genome-wide association studies (GWAS) in the general population, six SNPs previously associated with GDM or glycaemic traits in pregnancy and 10 SNPs previously associated with both T2DM/fasting glucose in the general population and GDM/glycaemic traits in pregnant women (Table S1 ). The selected SNPs were from studies in the general population published up to 2013, from two large meta-analyses of GDM, 7, 8 and from one GWAS of glycaemic traits in pregnant women. 15 If two or more variants were in linkage disequilibrium (r 2 >.5), we selected the variant that was directly associated with GDM or tag variants. 
| Statistical analysis
Demographic and clinical characteristics were described as frequen- To study the combined effect of all SNPs on the risk of GDM, a simple-count (0, 1, 2 for each risk allele) GRS was used in the logistic regression analysis (Table S1 ). Patients missing information for four or more SNPs were excluded from the risk score calculation. In patients with incomplete genotypes for three or fewer SNPs, we took the conservative approach of assuming that they did not carry the risk allele (ie we assigned a score of zero for the missing genotype). In a sensitivity analysis, we excluded all patients with missing genotypes. Based on quintiles derived from the number of risk alleles, ORs and 95% CI were calculated using the lowest quintile as reference. 
| RESULTS
| Population characteristics
Among Caucasian pregnant women, we identified 619 cases of GDM and 1687 controls (Figure 1) , and 458 cases and 1538 controls had genotype data and were included in the analysis. (Figure 1 ). Cases of GDM had higher parity, prepregnancy BMI and predelivery BMI compared to controls (P<.01 for all comparisons, Table 1 ). Prepregnancy BMI was missing in 34% of cases and 7% of controls, and predelivery BMI was missing in 8% of cases and 3% of controls.
| Single-SNP analysis
Genotypes were all in Hardy-Weinberg equilibrium and within expected frequency (Table S1 ). In single-SNP analyses, the OR adjusted and rs4506565 in TCF7L2) (Table S2 ).
| Genetic risk score
There was significant overlap in the distribution of the GRS between cases and controls. However, the mean±standard deviation (SD) of 38.9±4.0 risk alleles in cases was significantly higher compared to 37.4±4.0 in controls (P=1.6×10 −11 ). The GRS was significantly associated with GDM; the OR associated with each additional risk allele was 1.10 (95% CI: 1.07-1.13, P=6×10 −11 ) for the single count GRS and 1.11 (95% CI: 1.08-1.14, P=3×10 
| DISCUSSION
The main finding of this study is that a GRS, which included SNPs known to be associated with T2DM, was associated with the risk of GDM in Caucasians but had limited discriminatory ability to identify cases of GDM. Additionally, several T2DM risk variants were associated with GDM for the first time.
The genetic contribution to the risk of GDM remains poorly defined. There have been several studies focused on a small number of known T2DM risk variants, summarized in two meta-analyses, 7, 8 as well as a single GWAS in GDM. 9 These studies suggested that some known T2DM risk variants are associated with GDM.
GDM is a precursor of T2DM in some women. Accordingly, we anticipated that a GRS that incorporated T2DM risk alleles would be associated with the risk of GDM. Cases of GDM indeed had a higher GRS than controls, but the discriminative ability of the GRS for GDM was modest. In T2DM, the overall discriminative accuracy (measured by the c-statistic) for genetic models are typically ~0.60
and for models using only clinical information range from 0.7 to 0.96. 16 Similar to our observations in GDM, others have reported that the addition of genetic information to clinical variables improved the prediction of T2DM modestly. 16 A previous study in GDM of a GRS composed of 11 T2DM variant 17 found a modest c-statistic for the GRS (0.68) that improved the clinical model (0.73).
Although we included several of the loci from that study and added loci that were subsequently associated with T2DM, the predictive ability of our GRS (single count and weighted) for GDM was ~0.60, which suggests that adding additional common T2DM variants with small effect sizes has small impact on genetically predicted risk of GDM, an observation also made in T2DM. 16 Thus, the observation that clinical risk factors themselves have a strong genetic component that is partially captured by the GRS in T2DM may also apply to gestational diabetes.
We used a simple GRS because for some of the risk alleles included there was inadequate information in the literature to assign a weight.
One could argue that a weighted risk score could have performed better. To begin to address this question, we used the effect sizes from the single-SNP analysis to construct an OR-weighted GRS. The ORweighted GRS and the simple-count GRS performed similarly, which has also been observed in T2DM.
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Although the GRS overall has limited discriminative value for GDM at the population level, it may improve risk stratification for some women. For example, each additional risk allele was associated with a 10% increased risk of GDM, and women with 42 or more risk alleles had more than 3-fold increased risk of GDM compared to women with 34 or fewer risk alleles. Thus, the GRS could provide information about the genetic burden in women at high risk of GDM in order to assist Concordant with previous studies, we observed associations between GDM and variants in IGF2BP2, TCF7L2, MTNR1B, HHEX/IDE and CDKAL1. [7] [8] [9] 17 Risk alleles in these loci have shown to decrease insulin response after glucose administration. [19] [20] [21] [22] [23] [24] [25] This suggests that the signals for these loci are more likely to be significant in conditions where β-cell response after glucose stimulation is impaired, such as occurs in GDM.
Current evidence indicates that these variants are likely to influence β-cell function through several molecular mechanisms (eg direct regulation of the corresponding gene or genes known to play a role in insulin activity and metabolic control 26, 27 ; interaction with local enhancers
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; alteration of splicing patterns
29
; or normal development of β cells 30, 31 ).
Additionally, we report for the first time associations between variants in PPARG and HKDC1 and the risk of GDM in Caucasians. The PPARG rs1801282 (C34G substitution ~ Pro12Ala) variant was associated with the risk of GDM. In the general population, the G allele (12Ala) is associated with reduced activity of PPARγ, improved insulin sensitivity 32 and reduced risk of T2DM. 33 Concordant with these findings, we found that carriers of the C allele (Pro12) had a higher risk of GDM compared to the G allele (12Ala). In the EDEN study, the C allele of rs1801282 was associated with the risk of GDM only when the T allele of another PPARG variant, rs3856806 (C1431T), that is in weak linkage disequilibrium with rs1801282 (D'=0.68, R 2 =.42) was present. 34 We did not genotype for this haplotype because it is uncommon (~4% in Caucasians). 34, 35 We also found that HKDC1 rs4746822 variant was associated with GDM. This variant was significantly associated with plasma glucose levels 2 hours after a glucose load in pregnant women in the Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO) study 15 and nominally associated with 2-hour glucose levels in the general population, 36 but has not previously been associated with T2DM.
A recent study has found for the first time that rs4746822 was significantly associated with the risk of GDM in Indian women. 37 The function of several variants in the HKDC1 region that are associated with gestational hyperglycaemia and are in linkage disequilibrium with rs4746822 has been studied in vitro. These variants, which are organized in different haplotypes, disrupt regulatory element activity and reduce expression on HKDC1, a gene that encodes for a novel form of hexokinase 38 that plays an important role in glucose utilization during pregnancy and ageing in animal studies.
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The GRS was significantly associated with the risk of GDM but the risk associated with individual SNPs varied; of the 34 SNPs in the GRS, 24 had an OR greater than 1, but only eight were associated with GDM with a P value <.05. Considering that the SNPs selected for the GRS were derived from large GWAS with thousands of participants and had small effects, it is not surprising that some SNPs were not significantly associated with GDM. Thus, a larger study would be needed to detect the contribution of variants with small effect sizes, since the current study was powered to detect ORs of 1.3 or larger.
Our study had limitations. First, we selected cases of GDM and controls using EMRs from patients seen at a tertiary care hospital.
Thus, the findings may not be applicable to all populations. However, cases and controls were carefully phenotyped and represent a broad spectrum of pregnant women. Second, although the two-step approach with 100-g OGTT is the gold standard for GDM diagnosis in the United States
13
; the WHO recommends a one-step 75-g OGTT to screen for GDM in developing countries in order to decrease costs with acceptable sensitivity. 2 Use of a different approach to ascertain cases of GDM could affect results. Third, we included only those SNPs most robustly associated with T2DM (ie significant in two or more GWAS). Although it is possible that including more SNPs could improve the performance of the GRS, it is likely that the largest improvement will result from the inclusion of fewer, more discriminatory SNPs with large effect size rather than multiple common variants with modest effects. Fourth, we did not have information about family history of T2DM. The addition of information about family history of T2DM might have improved the predictive ability of the clinical model and further reduced the impact of the genetic score by incorporating some of the information present in the GRS. Fifth, although we adjusted for parity in our analysis to account for differences between cases and control women, we cannot exclude the possibility that some controls may have developed GDM in future pregnancies and were therefore misclassified in our study. Such misclassification would have acted to impair our ability to detect genetic differences between cases and controls. Sixth, we cannot exclude the possibility that a low frequency or rare variants with large effects may contribute to the risk of GDM, as has been shown in T2DM.
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| CONCLUSIONS
In summary, we found that a GRS that includes T2DM variants was associated with increased risk of GDM, but the improvement in the discriminatory accuracy for genetics added to clinical factors for predicting GDM was moderate and similar to that observed in T2DM. We also report for the first time that polymorphisms in PPARG and HKDC1
were associated with increased risk of GDM in Caucasians.
